Deep mutational scanning of Pneumocystis jirovecii dihydrofolate reductase reveals allosteric mechanism of resistance to an antifolate

PLoS Genet. 2024 Apr 29;20(4):e1011252. doi: 10.1371/journal.pgen.1011252. eCollection 2024 Apr.

Abstract

Pneumocystis jirovecii is a fungal pathogen that causes pneumocystis pneumonia, a disease that mainly affects immunocompromised individuals. This fungus has historically been hard to study because of our inability to grow it in vitro. One of the main drug targets in P. jirovecii is its dihydrofolate reductase (PjDHFR). Here, by using functional complementation of the baker's yeast ortholog, we show that PjDHFR can be inhibited by the antifolate methotrexate in a dose-dependent manner. Using deep mutational scanning of PjDHFR, we identify mutations conferring resistance to methotrexate. Thirty-one sites spanning the protein have at least one mutation that leads to resistance, for a total of 355 high-confidence resistance mutations. Most resistance-inducing mutations are found inside the active site, and many are structurally equivalent to mutations known to lead to resistance to different antifolates in other organisms. Some sites show specific resistance mutations, where only a single substitution confers resistance, whereas others are more permissive, as several substitutions at these sites confer resistance. Surprisingly, one of the permissive sites (F199) is without direct contact to either ligand or cofactor, suggesting that it acts through an allosteric mechanism. Modeling changes in binding energy between F199 mutants and drug shows that most mutations destabilize interactions between the protein and the drug. This evidence points towards a more important role of this position in resistance than previously estimated and highlights potential unknown allosteric mechanisms of resistance to antifolate in DHFRs. Our results offer unprecedented resources for the interpretation of mutation effects in the main drug target of an uncultivable fungal pathogen.

MeSH terms

  • Allosteric Regulation
  • Catalytic Domain / genetics
  • Drug Resistance, Fungal* / genetics
  • Folic Acid Antagonists* / pharmacology
  • Fungal Proteins / chemistry
  • Fungal Proteins / genetics
  • Fungal Proteins / metabolism
  • Humans
  • Methotrexate* / pharmacology
  • Mutation*
  • Pneumocystis carinii* / drug effects
  • Pneumocystis carinii* / enzymology
  • Pneumocystis carinii* / genetics
  • Saccharomyces cerevisiae / drug effects
  • Saccharomyces cerevisiae / genetics
  • Tetrahydrofolate Dehydrogenase* / chemistry
  • Tetrahydrofolate Dehydrogenase* / genetics
  • Tetrahydrofolate Dehydrogenase* / metabolism

Substances

  • Tetrahydrofolate Dehydrogenase
  • Folic Acid Antagonists
  • Methotrexate
  • Fungal Proteins

Grants and funding

The project was funded by a Canadian Institutes of Health Research Foundation to CRL (387697, https://cihr-irsc.gc.ca/), a FRQNT Team Grant (2022-PR-298169, https://frq.gouv.qc.ca/en/) and a Genome Canada and Genome Quebec grant (6569, https://genomecanada.ca/). CRL holds the Canada Research Chair in Cellular Systems and Synthetic Biology (https://www.chairs-chaires.gc.ca/home-accueil-eng.aspx). FDR was supported by fellowships from FRQNT, PROTEO, EvoFunPath NSERC CREATE program and the Vanier Canada Graduate Scholarship agency. SD was supported by a fellowship from FRQNT. PCD was supported by fellowships from the FRQS and from the Vanier Canada Graduate Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.